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7 of 10 patients. PFS was 7.4 months and the estimated PFS 
using routine data was 9.1 and 7.8 months with methods 1 
and 2 respectively. There was acceptable agreement between 
reference and routine data in 49 of 50 patients for OS and 35 
of 50 patients for PFS. The event of progression, subsequent 
treatment and OS are well estimated using our approach, but 
PFS estimation is less accurate. Our approach could refine 
our understanding of the disease course and allow us to report 
PFS, OS and treatment nationally.
Keywords Glioblastoma · Routine data · Overall 
survival · Progression free survival
Introduction
Glioblastoma (WHO grade IV glioma; GBM) is a rare 
tumour with 79,000 new cases worldwide per year. However, 
it represents 1/3rd of primary brain tumours, and 80% of all 
primary malignant brain tumours in adults [1]. Survival is 
poor, and even with aggressive treatment the median sur-
vival is 15 months. Although life expectancy is important, 
many patients also want to know how long it will be until 
they are less well. The development of progressive disease 
is an important event for patients and their families, and 
there is a clear correlation between disease progression and 
deterioration of both functional status and quality of life [2, 
3]. The anatomical location of a glioblastoma within the cen-
tral nervous system leads to different clinical presentation 
of neurological impairments of varying degrees. Therefore 
functional status and subsequently quality of life is depend-
ent on the neurological impairment at presentation and dis-
ease progression. Clinical trials provide the best quality data 
on treatment and progression but less than 10% of patients 
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are enrolled in clinical trials, and those who are enrolled 
differ from those treated in routine care [4].
To measure outcomes in routine practice, prospectively 
collected manual data (as in clinical trials) remains the gold 
standard. However, this is time consuming and expensive, 
and there is increasing interest in the use of routinely col-
lected electronic health data [5]. Such data is typically gen-
erated as a by-product of care, such as prescriptions and 
billing, and have the advantage of being available at a large 
scale and for relatively little cost when compared to dedi-
cated multi-centre manual data collection. Although we can 
measure overall survival (OS) from routinely collected data 
[6], the challenge remains to estimate disease progression, 
and progression-free survival (PFS), from these data sets. 
The ability to do this would allow us to assess these out-
comes, which are of significant relevance to patients, at a 
national level relatively quickly and cheaply. We have pre-
viously used electronic data to estimate disease progression 
in patients with head & neck cancers [7, 8], and others have 
used similar approaches in breast cancer [9]. However, there 
has been no work in patients with brain tumours.
In this pilot study, we extend our previous work to 
patients with glioblastoma receiving chemo-radiotherapy. 
We assess whether we can estimate rates of progression and 
PFS using routinely collected electronic data, and compare 
that estimate with the actual rate of progression and PFS 
based on manually curated patient data.
Method
We identified a pilot group of 50 patients with histologi-
cally confirmed glioblastoma (WHO grade IV glioma) who 
received chemo-radiotherapy in a single center under the 
care of a single treating consultant oncologist. Data collec-
tion was completed on 30th April 2016.
The standard practice for patients with glioblastoma 
receiving treatment in our center consists of neurosurgical 
tissue sampling (with surgical resection where possible), fol-
lowed by chemo-radiotherapy (60 Gy in 30 fractions over 6 
weeks) with concurrent chemotherapy (temozolomide 75 mg/
m2). Patients undergo an MRI scan 3 weeks after the end 
of chemo-radiotherapy, and then receive 6 or 12 cycles of 
adjuvant temozolomide (150–200 mg/m2), depending on 
patient choice. This is identical to the regimen used in the 
randomized phase III trial [10], but with the consideration 
of delivery of an additional six cycles of temozolomide. 
Patients who have imaging suggestive of progression on 
their scan post chemo-radiotherapy are assessed clinically. 
If well, they continue with temozolomide and have a repeat 
MRI scan after 2 (rather than 3) cycles of chemotherapy. 
If sequential MRIs show deterioration in appearances, we 
regard the initial MRI as showing true (rather than pseudo) 
progression. Progression is confirmed on serial MRI, using 
RANO criteria, with all scans reviewed by an experienced 
neuro-radiologist.
Reference data
For each patient, we manually extracted a reference data set 
from multiple sources (clinic letters, multidisciplinary meet-
ing outcome proformas, pathology results system, discharge 
summaries, radiotherapy and chemotherapy treatment sum-
maries and hospital notes) as a summary of their diagnosis, 
treatment and outcomes. This was our reference data set. 
Overall survival was the interval from the date of histological 
diagnosis to date of death or last follow-up. Progression- free 
survival was the interval from histological diagnosis to the 
first radiological evidence of disease progression (on MRI), or 
date of last follow-up or death, whichever was earlier (Fig. 1).
Routine data
For each patient, we also obtained a routine data set by 
combining local data on inpatient care, radiotherapy and 
chemotherapy (see Appendix). We extracted dates of hospi-
tal admissions, diagnoses and surgical procedures, chemo-
therapy regimens, dates, number of cycles and duration of 
treatment and radiotherapy dates, duration of treatment, dose 
and fractionation. We added data on deaths from the national 
personal demographics service. The date of last follow-up 
was obtained from the electronic hospital records system, 
and date of death from NHS personal demographics service.
Routine data sources do not explicitly contain date of 
diagnosis or progression. We therefore used clinical events 
in the routine data to estimate these. Progression was esti-
mated using two methods; method 1 used the start of second 
line treatment (further neurosurgical resection, administra-
tion of second line chemotherapy or re-irradiation) as evi-
dence of progression. Method 2 used either start of second 
line treatment (as method 1) or cessation of first line treat-
ment as a marker of progression (Fig. 1). Concurrent or 
adjuvant chemo- or radiotherapy was not considered to be 
evidence of recurrence. Progression-free survival was esti-
mated as the interval between the date of diagnosis and the 
estimated date of progression or death or end of follow-up.
Outcome measures
The primary outcome measure was per-patient agree-
ment for PFS between the reference and routine data sets. 
Overall and progression-free survival intervals from the 
reference and routine data sets were considered to have 
acceptable agreement if the ratio between the two intervals 
was between 0.75 and 1.25. Our secondary outcomes were 
correlation between reference and routine datasets for PFS 
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and OS (using Kendall’s t test), and per-patient agreement 
between the manual and reference datasets for OS. We also 
calculated the performance of the routine data to detect 
progression, using a standard 2 × 2 table and associated 
measures (supplementary table 2 & 3).
Ethical considerations
Ethical approval was not required for this retrospective 
study and it was registered as a clinical audit reference 
number 1900 at Imperial College Healthcare NHS Trust.
Fig. 1  Relative time points in the manual and routine dataset
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Results
Patient characteristics
We identified fifty patients. 30 were male, 20 were female, 
and the median age was 58 (supplementary table 1). All 
50 patients received external beam radiotherapy (60 Gy in 
30 fractions) with concurrent temozolomide chemotherapy 
(75 mg/m2). All were WHO performance score 0–1. Forty-
five patients had de-bulking surgery (29 gross total resec-
tion, 16 sub-total resection) and five patients only underwent 
biopsy.
Survival and recurrence
Overall survival was 68% at 1 year, median OS was 
12.8 months and median PFS was 7.4 months. At the time 
of analysis 40 of the 50 patients had developed progres-
sive disease and 25 of the fifty patients had died. Of the 40 
patients who developed progressive disease, 25 commenced 
second line treatment. Seventeen of the 25 patients received 
second line chemotherapy (11 lomustine, 1 carboplatin, 2 
metronomic temozolomide, 1 bevacizumab with irinotecan, 
1 PCV and 1 phase I clinical trial), 5 had further surgery 
and 3 had further radiotherapy. Fifteen patients received no 
second line treatment due to deterioration in clinical status.
Using the routine data, OS was estimated as 66% at 1 year 
and median OS at 12.9 months (Fig. S1). Using method 1, 
median PFS was estimated at 9.1 months and using method 
2 it was estimated to be 7.8 months (Figs. S2 and S3).
Data agreement and discrepancies
For 49 of the 50 patients, there was acceptable agreement 
(i.e. estimated interval 0.75–1.25 of the actual time interval) 
for OS between the two datasets.
Of the 40 patients who developed progressive disease, 
method 1 correctly identified 23 and method 2 correctly iden-
tified 37. Of the 23 patients identified with progressive disease 
by method 1, 15 had an acceptable agreement for estimated 
PFS with the reference data. Method 2 had an acceptable 
agreement for 23 of the 37 identified. Of the 10 patients who 
did not develop progressive disease, method 2 correctly iden-
tified 7. Overall survival and progression-free survival curves 
of manual versus routine data sets are shown in Figs. 2 and 3.
Thirty-one of the 50 patients had acceptable agreement 
for PFS by method 1 and 35 patients by method 2. The rou-
tine data over-estimated the progression-free interval in 14 
patients by a median of 3.5 months with method 2 and in 
19 patients by a median of 5.4 months with method 1. The 
routine data underestimated PFS in 1 patient by 8.7 months 
with method 2.
Correlation and probability
There was good correlation for OS between the reference 
and routine data sets (Kendall’s tau = 0.86; p < 0.0001) (Fig. 
S1). The correlation between the two data sets for PFS was 
less good (tau = 0.62; p < 0.0001 and 0.70; p < 0.0001 for 
methods 1 and 2 respectively) (Figs. S2, S3).
The sensitivity that a patient with progressive disease was 
correctly identified by the routine data is 93% and specific-
ity that a patient without progressive disease was correctly 
identified is 70%, with a positive predictive value (PPV) of 
93% and a negative predictive value (NPV) of 70%.
The probability that a patient who developed progressive 
disease was both identified and had a reasonable estimate 
of PFS (“acceptable interval sensitivity”—AISens) was 
Fig. 2  Overall survival in days (by two different methods)
Fig. 3  Progression free survival in days (by three different methods)
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58%. The AISens and AISpec of method 2 are 58 and 70% 
respectively, with an AIppv of 88%, and an AInpv of 29% 
(supplementary table 3).
Discussion
We have presented a method to estimate disease progres-
sion, progression free survival and overall survival from 
routinely collected data in patients with glioblastoma 
receiving concurrent chemo-radiotherapy, and evaluated it 
in a group of 50 patients. Our results are summarised in 
Table 1. Overall survival and the fact of progression are 
well estimated using this approach, although PFS estima-
tion is less accurate. The commonest reason for our method 
to underestimate recurrence was a patient not receiving 
second-line treatment. The main reason for a discrepancy 
between actual and estimated PFS was the possibility of 
pseudo-progression, which as discussed above, can only be 
determined in retrospect. In theory, our results could be 
confounded by radionecrosis, but given the low incidence 
of this (approximately 5% at 1 year) and a median follow-up 
in our survivors of 13 months, it is unlikely that it signifi-
cantly influenced our results [11]. Details of the reasons for 
discrepancies are given in Table 2.
Approximately 5% of glioblastoma are secondary, having 
transformed from a prior low-grade glioma. Unfortunately, 
both ICD-9 and ICD-10 coding schemes includes grade II, 
III and IV tumours within the same category. Therefore a 
patient who had a grade II astrocytoma that transformed into 
a grade IV tumour some years later, and had surgery for both 
tumours, would have a discrepancy of years between the 
manual and routine dataset. This reinforces the importance 
of using both histology codes and ICD9/10 codes in patients 
with brain tumours, as opposed to other tumour sites, where 
ICD codes alone may suffice.
We have assessed the performance of two methods for 
estimating PFS from routine electronic healthcare data. 
Method 1 used initiation of second line treatment as evi-
dence of progression. Method 2 used either initiation of 
second line treatment or cessation of planned first line treat-
ment as markers of progression. As method 2 took account 
of more of the data, we expected some degree of improve-
ment of our results in reflecting an accurate clinical picture. 
If we did not incorporate cessation of first line treatment 
into our methodology we would not detect the patients who 
clinically deteriorated and stopped first line treatment and 
would only be detecting progression in patients who were 
fit for second line treatment. Given the better performance 
of method 2 we would use this in future work as it more 
accurately estimates progression. There may be other areas 
where this approach is applicable, but it depends on being 
able to define the ‘expected’ clinical course. The extent to 
which this is feasible is likely to differ across disease types 
and treatment pathways.
The commonest reason for failing to detect progression 
was not offering second-line treatment. However, this is 
heavily influenced by patient fitness, and is likely to be 
non-uniformly distributed. In principle, we should be able 
to develop stratified algorithms that have different perfor-
mance in different subsets of patients, but our pilot study 
is too small to explore this. In the phase 3 trial demon-
strating the benefit of temozolomide, approximately 60% 
of patients who received chemo-radiotherapy had second-
line treatment after progression, comparable to the figures 
in our cohort.
Table 1  Identification of 
progressive and stable disease, 
and PFS and OS intervals by the 
manual and routine data sets
Number of patients identified Progressive 
disease
Stable disease OS agreement PFS agreement
Manual data 40 10 NA NA
Correctly by routine data (method 1) 23 10 49 15
Incorrectly by routine (method 1) 0 17 1 8
Correctly by routine data (method 2) 37 7 49 23
Incorrectly by routine data (method 2) 3 3 1 14
Table 2  Reason for 
discrepancy between actual and 
estimated PFS
Reason for disagreement between actual and estimated PFS Number of 
patients
Evidence of progressive disease on imaging post chemo-radiotherapy but delay in commenc-
ing second line treatment to rule out pseudoprogression
11
Progressive disease post operatively but continued with first line treatment 1
Initiation of second line treatment due to intolerance of first line treatment 1
Cessation of first line treatment due to patient choice 1
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Previous work in this area has estimated mortality after 
orthopaedic surgery [12] and oncological treatment [13]. 
Cancer registry data can be used to measure recurrence rates 
in breast cancer [9], but there is little work on using routinely 
available procedure-level data to infer disease recurrence or 
PFS. One study examined the use of such data to estimate 
measures of metastatic disease in breast, prostate and lung 
 cancer, while another used patients enrolled in a clinical 
trial, and we have previously published work on estimating 
PFS in patients with head and neck cancer [7, 8, 14, 15]. 
All four studies used a combination of clinical intuition and 
logically-described criteria to interpret routine data and infer 
recurrence. Our work is distinguished from these on three 
grounds. Firstly, this is the first work in patients with brain 
tumours and secondly, we consider a wider range of inter-
ventions (surgery, chemotherapy, radiotherapy) as markers 
of progressive disease. Finally, we have refined our previous 
approach to consider both initiation of new treatment and 
cessation of planned treatment, which improves the estima-
tion of PFS.
Various authors have reported OS from routine data [6, 
16] in large national cohorts for patients with aggressive 
brain tumours, and PFS from clinical trials [17] but there 
are no reports of progression rates or PFS in large cohorts 
treated in routine care. We note from the same dataset we 
have used we can also report the number and length of hos-
pital admissions, number of neurosurgical procedures and 
total number of treatment lines and time to second progres-
sion, and we believe that assessing these non-OS based out-
comes needs to become a key part of comparative effective-
ness research.
This study pilots our methodology on a group of 50 
patients to assess its ability to correctly highlight progres-
sion and estimate progression free and overall survival. 
It directly compares this routinely collected data with a 
manually collected data set to assess the accuracy of this 
technique. After validating our method in this pilot we 
will use the same technique on a national cohort of 4600 
patients with glioblastoma, of whom 1500 have received 
chemo-radiotherapy. This national cohort is composed 
of patients treated by a range of neuro-oncologists, in a 
variety of institutions and is comprised of patients who 
had treatment with radical intent to those who had pallia-
tive treatment. By including this cross section of patients 
we will be able to inform newly diagnosed patients and 
the families more accurately of their expected disease 
trajectory.
The approach outlined in this paper is conceptually sim-
ple and when applied to large-scale national datasets, such 
as those reported in the USA [18], Australia [19], France 
[20] and recently England [6], we should be able to report 
and compare PFS, OS, treatment and hospital admissions at 
a national level. This work is currently being planned.
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Appendix
Sources of data: acronyms and types of data available
National Cancer Registration data (NCRAS): Data on on 
incidence, demographics and mortality Hospital Episode 
Statistics (HES): Data on inpatient care—diagnoses and pro-
cedures Radiotherapy Dataset (RTDS): Data on radiother-
apy—dates, dose and fractionation Systemic Anti-Cancer 
Therapy dataset (SACT): Chemotherapy—drug and regimen 
names, dates and doses
Examples of neurosurgical OPCS codes
OPCS code Procedure
Debulk A021 Excision of lesion of tissue of frontal lobe of 
brain
A022 Excision of lesion of tissue of temporal lobe 
of brain
A023 Excision of lesion of tissue of parietal lobe of 
brain
A024 Excision of lesion of tissue of occipital lobe 
of brain
V051 Extirpation of lesion of cranium
Biopsy A043 Open biopsy of lesion of tissue of parietal lobe 
of brain
A081 Biopsy of lesion of tissue of frontal lobe of 
brain
A082 Biopsy of lesion of tissue of temporal lobe of 
brain
A083 Biopsy of lesion of tissue of parietal lobe of 
brain
A084 Biopsy of lesion of tissue of occipital lobe of 
brain
A088 Other specified other biopsy of lesion of tissue 
of brain
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